Shift Bioscience is harnessing AI-powered virtual cells to fight diseases of aging. Cell reprogramming with Yamanaka factors can reverse aging in human cells and ameliorate disease in mammals but its tumor-inducing potential hampers clinical development. Shift has harnessed AI-powered virtual cells to bring forward centuries of experiments and decouple the tumor-inducing pathway in human fibroblasts. Shift is pursuing an intervention applicable to multiple cell types, promising a universal therapeutic approach that could sustain health well into old age and beyond. Shift Bioscience was founded in 2017 by Daniel Ives, CEO, and Brendan Swain, CSO. Its labs are based at the Gurdon Institute, Cambridge thanks to the Frame Shift bio-incubator, an initiative of the Milner Therapeutics Institute.
